Treatment strategies for patients with metal allergies undergoing percutaneous coronary intervention / 中华老年医学杂志

Percutaneous coronary intervention is an extremely effective method for the treatment of acute myocardial infarction.In some patients, allergic reactions to metals such as in-stent restenosis and coronary aneurysm dilatation will occur.Currently, treatment options for such patients remain controversial.Studies have shown that nickel is a common cause of recurrent in-stent restenosis.

Change level of serum homocysteine, folic acid and vitamin B12 levels in young patients with ischemic stroke and the effect of the intervention / 中国综合临床

Objective To explore the variations and prognostic factors of hyperhomocysteinaemia in ischemic cerebral apoplexy for the youth who administrated vitamin B6,vitamin B12 and folic acid at pretherapy and post-treatment.Methods One hundred and twenty cases of young patients with ischemic cerebral apoplexy in the Pinggu Hospital of Capital University from January 2003 to December 2013 as case group(intervention group,60 cases and 60 cases of non-intervention group),while 120 youth volunteers with the same period and age without neurological diseases as a control group.Both groups patients were detected for hyperhomocysteinaemia,folic acid and vitamin B12.The non-intervention group was administrated basic treatment,while the intervention group administrated vitamin B6,vitamin B12 and folic acid on this basis.The hyperhomocysteinaemia,folic acid and vitamin B12 were detected repetitively after four weeks.Results Compared with control group,the hyperhomocysteinaemia in ischemic cerebral apoplexy group for the youth had increased significantly ((10.2 ± 3.1) μmmol/L vs.(21.3 ± 4.5) μmmol/L,P ＜ 0.05).The hyperhomocysteinaemia,folic acid and vitamin B12 had no significant differences between intervention group and non-intervention group (P ＞ 0.05).After replenished vitamin B6,vitamin B12 and folic acid,the hyperhomocysteinaemia had decreased significantly ((10.5 ± 3.0) μmnol/L) in intervention group.Folic acid ((6.5±2.8)μg/L) and vitamin B12(450.2±155.6) ng/L) had increased significantly(P＜0.05).Conclusion The hyperhomocysteinaemia increased in ischemic cerebral apoplexy for the youth.It is that hyperhomocysteinaemia decreased by replenished vitamin B6,vitamin B12 and folic acid which make for prognosis in ischemic cerebral apoplexy for the youth.

Risk assessment of epilepsy recurrence of patients with single post-stroke epilepsy based on the new epilepsy definition / 中国综合临床

Objective To analyze the recurrence risk of patients single post-stroke epilepsy. Methods Fifty-eight cases of epilepsy after stroke in Pinggu District Hospital of Beijing were enrolled in this study and their history clinical information were retrospectively collected. All patients were divided into single attack group (A group)and two or more attack group(B group). Results There were 3. 67%(58/1580)stroke patients were developed epilepsy. Among them,0. 38%(6/58)of patients were developed seizures in early stage,and 3. 29%(52/58)in late stage. Thirty-one cases occurred epilepsy once within one years in A group and 27 cases occurred epilepsy more than twice with one year in B group. Initiate epilepsy onset of 2 cases(A1)was at early stage and 29 cases(A2)at late stage in A group. Initiate epilepsy onset of 3 case(B1)was at early stage and 24 cases(B2)at late stage in B group. There was no significant difference in term of types of epilepsy between two groups(χ2 =0. 001,P﹥0. 05). The lesions site of 13 cases was located cortex and 18 cases was located in below cortex in A group,in B group,the lesions site was located in cortex of 17 cases or below cortex of 10 cases,and the difference was not significant(χ2 =2. 555,P﹥0. 05). The hemorrhagic stroke and ischemic stroke were 12 and 19 cases in A group,10 and 17 cases in B group,and there was no significant difference between two groups (χ2 =0. 017,P﹥0. 05). Rhythm of slow wave and the epileptiform discharges were 11 and 2 cases in A group, 11 and 13 cases in B group. About 51. 8% of the patients with recurrence of epilepsy had history of infection in B group. Conclusion For stroke patients,especially hemorrhagic stroke,first seizure is late-onset epilepsy cases. If the electrical activity of the brain is abnormal slow rhythm or epileptiform discharges,close to the cortex is more likely to cause epilepsy recurrence. It is supposed to giving positive antiepileptic drug treatment in the first epilepsy after stroke.

Influences of Site-directed Mutagenesis of a Recombinant Didintegrin from Gloydius blomhoffi brevicaudus on Its Biological Activities / 中国生物化学与分子生物学报

Arg-Gly-Asp (RGD) is a unique minimal integrin-binding sequence found within several glycoprotein ligands and also in snake-venom disintegrins. Adinbitor, a protein with 73 amino acid residues including 12 cysteins and an RGD motif, was cloned from Gloydius blomhoffi brevicaudus in my laboratory. As a new member of disintegrin family, adinbitor can inhibit both human platelet aggregation induced by ADP and angiogenensis in vivo and in vitro, the typical characters of disintegrin family. To separate the effect of inhibiting platelet aggregation from that of inhibiting angiogenensis, the motif KGD was introduced into adinbitor cDNA to replace RGD by site-directed and PCR-based mutagenesis. The recombinant protein (recombinant adinbitor (KGD)) was expressed in E. coli BL21 and purified through the His· Bind affinity chromatography. Recombinant adinbitor (KGD) could inhibit ADP-induced platelet aggregation with IC50 value of 85 nmol/L. Considerably, it was a more effective inhibitor on platelet aggregation than recombinant adinbitor (RGD), which has an IC50 of 150 nmol/L. Interestingly, recombinant adinbitor (KGD) has no potency in inhibiting angiogenesis in vivo compared with recombinant adinbitor (RGD). These findings showed that KGD containing adinbitor was more suitable for inhibiting ADP-induced human platelet aggregation as a potential and specific inhibitor of human platelet aggregation, which might have promising therapeutic potential as an antithrombotic agent.